AI assistant
Lupin Ltd — Regulatory Filings 2026
Feb 16, 2026
61031_rns_2026-02-16_e7566f78-a657-4014-bfaa-93172b37360f.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [79 x 93] intentionally omitted <==
February 16, 2026
National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Symbol: LUPIN
BSE Limited
P. J. Towers, Dalal Street, Mumbai Samachar Marg, Mumbai - 400 001
Scrip Code: Equity - 500257
Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
Dear Sir/Madam,
We are pleased to enclose a Press Release titled “Lupin Signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex™ in Canada”.
The same is for your information and dissemination.
Thanking you,
For LUPIN LIMITED
AMIT Digitally signed by AMIT KUMAR GUPTA DN: c=IN, st=Maharashtra, 2.5.4.20=f72cf02f52d2a7e595b45b84659bd ca28c8f26a939bb35835a169f2a237229a3, postalCode=400705, street=C701 Shivdarshan CHS Ltd Sector16 Plot No5 Navi Mumbai, KUMAR pseudonym=d3a468d0d03546efabffd2a7cb7aaaae, title=7875, serialNumber=de9bbd80d8994e4be9f0dd2 399144eba7e782d70287df6aad1994f0b522 GUPTA fa08a, o=Personal, cn=AMIT KUMAR GUPTA Date: 2026.02.16 15:28:13 +05'30'
AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754)
Encl.: a/a.
LUPIN LIMITED
Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.
Corporate Identity Number: L24100MH1983PLC029442 [email protected] | www.lupin.com
Press Release
==> picture [68 x 70] intentionally omitted <==
BSE: 500257 NSE: LUPIN
REUTERS: LUPIN.BO BLOOMBERG: LPCIN
Lupin Signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex™ in Canada
Partnership aims to expand CNS portfolio and provide unique treatment options for the management of Major Depressive Disorder
Mumbai, Montreal, February 16, 2026: Global pharma major Lupin Limited (Lupin), today announced that it has signed a licence and supply agreement with Spektus Pharma (Spektus), a specialty pharmaceutical company to commercialize the novel antidepressant DeslaFlex™ in Canada.
DeslaFlex™ is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab™ oral drug-delivery platform.
This strategic partnership combines Lupin’s strong commercial footprint in Canada and Spektus’s capabilities in developing differentiated, novel formulations to successfully introduce DeslaFlex™ and establish a robust platform for future launches. The collaboration further strengthens Lupin’s CNS portfolio with physician-endorsed, value-added therapies, well aligned with a supportive regulatory environment.
“This milestone reinforces our long-term commitment to advancing Lupin’s CNS footprint and deepens our commitment to Canadian healthcare. The addition of DeslaFlex™ to our portfolio provides patients and clinicians with much-needed flexibility in the management of Major Depressive Disorder, enabling clinicians to deliver more personalized, patient-focused care,” said Claus Jepsen, President, Global Specialty, Lupin.
Zarvaan Merchant, Chief Executive Officer of Spektus Pharma, said, “This partnership with Lupin represents a key milestone as Spektus transitions from development to commercial execution. Lupin’s global brand and established commercial strength in Canada make it an ideal partner to realize the full value of DeslaFlex™ for patients across this important market.”
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
Page 1 of 2
Press Release
==> picture [68 x 70] intentionally omitted <==
BSE: 500257 NSE: LUPIN
REUTERS: LUPIN.BO BLOOMBERG: LPCIN
About Spektus Pharma
Spektus Pharma is a growth-stage pharmaceutical company focused on developing and commercializing value-added CNS therapies. Using its proprietary drug-delivery platforms such as Flexitab™ and AmyloFlex™, the company unlocks clinically relevant advantages for established molecules — including enhanced dosing flexibility, improved patient compliance, and expanded label opportunities — addressing unmet needs across depression, pain, and ADHD. Headquartered in Laval, Quebec, Spektus leverages a global partner network to bring these optimized medicines to patients worldwide. For more information, visit www.spektuspharma.com
For further information or queries, please contact:
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin [email protected]
*Safe Harbor Statement
Page 2 of 2